RMTI

+ Watchlist + Portfolio

Rockwell Medical, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $7.50
52-Week Range: $4.89 – $21.00
Market Cap: $30.79M
P/E (TTM): —
EPS (TTM): -1.32
Dividend Yield: —

Advanced Metrics

Price/Book: 0.84
PEG Ratio: 4.43
Return on Equity: -15.53%
Return on Assets: -5.18%
Gross Margin: 17.71%
Operating Margin: -5.97%
Profit Margin: -7.33%
Current Ratio: 3.25
Debt/Equity: 0.40
Total Debt: $13.93M
Free Cash Flow: $350.38K
Revenue Growth: 10.60%
Earnings Growth: —
Enterprise Value: $19.36M

RMTI Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$72.81M	$83.61M	$101.49M	$69.26M
Cost of Revenue	$68.73M	$74.91M	$84.00M	$57.56M
Gross Profit	$4.08M	$8.70M	$17.48M	$11.70M
Research & Development	$3.12M	$1.11M	$19.00K	$0.00
Selling, General & Admin	$17.74M	$14.27M	$16.86M	$16.39M
Operating Expenses	$20.86M	$15.37M	$16.88M	$16.39M
Operating Income	-$16.78M	-$6.67M	$608.00K	-$4.69M
EBITDA	-$16.17M	-$4.69M	$2.95M	-$2.00M
Pretax Income	-$18.68M	-$8.44M	-$480.00K	-$5.31M
Net Income	-$18.68M	-$8.44M	-$480.00K	-$5.31M
Diluted EPS	-18.90	-3.70	-0.30	-1.50
Diluted Shares	986684	2.33M	3.11M	3.60M

RMTI Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$10.10M	$8.98M	$15.66M	$10.71M
Receivables	$6.26M	$10.90M	$8.29M	$8.14M
Inventory	$5.81M	$5.87M	$5.78M	$3.42M
Current Assets	$35.31M	$28.77M	$37.03M	$38.16M
Total Assets	$46.63M	$52.17M	$59.21M	$57.15M
Current Liabilities	$17.69M	$16.64M	$14.09M	$9.58M
Long-Term Debt	$7.55M	$8.29M	$8.47M	$8.83M
Total Debt	$16.36M	$13.44M	$13.54M	$12.47M
Total Liabilities	$32.53M	$30.88M	$26.62M	$20.16M
Retained Earnings	-$388.76M	-$397.20M	-$397.68M	-$402.99M
Shareholders' Equity	$14.11M	$21.29M	$32.59M	$36.98M
Working Capital	$17.62M	$12.13M	$22.94M	$28.58M

RMTI Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$16.93M	-$9.41M	$4.20M	-$659.00K
Capital Expenditure	-$281.00K	-$284.00K	-$1.01M	-$542.00K
Free Cash Flow	-$17.21M	-$9.70M	$3.19M	-$1.20M
Depreciation & Amortisation	$576.00K	$1.44M	$2.18M	$2.19M
Stock-Based Compensation	$315.00K	$932.00K	$1.29M	$1.82M
Investing Cash Flow	-$2.40M	-$3.04M	-$4.87M	-$8.54M
Financing Cash Flow	$16.15M	$11.34M	$7.35M	$4.25M
Share Repurchases	$0.00	—	—	—
Net Change in Cash	-$3.17M	-$1.11M	$6.68M	-$4.95M

RMTI Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$18.91M	$16.07M	$15.93M	$18.35M	$17.34M
Cost of Revenue	$15.87M	$13.57M	$13.65M	$14.47M	$14.44M
Gross Profit	$3.04M	$2.50M	$2.27M	$3.88M	$2.90M
Research & Development	$0.00	$0.00	$0.00	$0.00	—
Selling, General & Admin	$4.40M	$3.85M	$3.86M	$4.28M	$4.38M
Operating Expenses	$4.40M	$3.85M	$3.86M	$4.28M	$4.38M
Operating Income	-$1.36M	-$1.35M	-$1.58M	-$398.00K	-$1.48M
EBITDA	-$699.00K	-$653.00K	-$924.00K	$278.00K	-$812.00K
Pretax Income	-$1.51M	-$1.49M	-$1.75M	-$554.00K	-$1.60M
Net Income	-$1.51M	-$1.49M	-$1.75M	-$554.00K	-$1.60M
Diluted EPS	-0.40	-0.50	-0.50	-0.10	-0.40
Diluted Shares	3.41M	3.43M	3.60M	3.94M	3.94M

RMTI Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$11.39M	$12.48M	$13.61M	$10.71M	$9.61M
Receivables	$9.67M	$8.08M	$8.33M	$8.14M	$8.82M
Inventory	$5.04M	$4.16M	$3.96M	$3.42M	$3.06M
Current Assets	$33.03M	$31.61M	$37.51M	$38.16M	$36.94M
Total Assets	$53.96M	$52.63M	$57.49M	$57.15M	$57.42M
Current Liabilities	$11.21M	$10.95M	$9.58M	$9.58M	$9.87M
Long-Term Debt	$8.56M	$8.65M	$8.74M	$8.83M	$8.21M
Total Debt	$12.87M	$14.01M	$13.13M	$12.47M	$14.39M
Total Liabilities	$22.44M	$22.22M	$20.47M	$20.16M	$21.57M
Retained Earnings	-$399.19M	-$400.69M	-$402.44M	-$402.99M	-$404.60M
Shareholders' Equity	$31.52M	$30.41M	$37.02M	$36.98M	$35.86M
Working Capital	$21.83M	$20.66M	$27.93M	$28.58M	$27.07M

RMTI Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$3.49M	$1.84M	-$1.31M	$2.29M	-$167.00K
Capital Expenditure	-$63.00K	-$164.00K	-$229.00K	-$86.00K	-$425.00K
Free Cash Flow	-$3.55M	$1.68M	-$1.54M	$2.21M	-$592.00K
Depreciation & Amortisation	$539.00K	$563.00K	$544.00K	$546.00K	$511.00K
Stock-Based Compensation	$445.00K	$382.00K	$532.00K	$457.00K	$479.00K
Investing Cash Flow	-$1.00K	-$103.00K	-$4.31M	-$4.13M	-$122.00K
Financing Cash Flow	-$783.00K	-$650.00K	$6.74M	-$1.06M	-$813.00K
Net Change in Cash	-$4.27M	$1.09M	$1.13M	-$2.90M	-$1.10M

Market Snapshot

About

Rockwell Medical, Inc. is a biopharmaceutical company targeting end-stage renal disease and chronic kidney disease with innovative products. The company develops and commercializes specialized drug therapies for dialysis patients, including iron replacement products and hemodialysis concentrate solutions. Rockwell Medical serves the dialysis market through its proprietary technologies and product portfolio.